Swissinfo: Swiss pharma giants fall in access to medicine ranking

Jessica Davis Plüss of Swissinfo writes about the 2022 Access to Medicine Index ranking and how pharma companies performed in on the Index ranking, particularly focusing on Swiss companies Novartis and Roche.

Access to Medicine Foundation CEO Jayasree K Iyer told the writer: “The Index is increasingly competitive. Every company is doing something to expand access, but the quality of the strategies is still lacking, especially when it comes to reaching all countries."

The article highlights the 2022 Index ranking, which sees GSK, Johnson & Johnson and AstraZeneca in the top three. It also also outlines how companies bring innovation and touches on key areas covered in the 2022 Index, including voluntary licensing, response to COVID-19, and access strategies.

Read the full article on the swissinfo website.